Illustration for: Vinci Pharmaceuticals Raises $8M For Eye Implant

Vinci Pharmaceuticals Raises $8M For Eye Implant

Vinci Pharmaceuticals raised more than $8 million in Series A funding, reportedly led by Dynagrow Capital, to advance EPIPLANT, a bioerodible implant designed to deliver drugs to retinal tissue without repeat injections.

VC
By Value Add VC · Value Add Pulse Funding Desk
Editor-in-chief: Trace Cohen
AI-assisted: drafted with AI from the cited sources — how we check it
1 min read
ShareXLinkedInEmail

THE RUNDOWN

1

EPIPLANT targets a real pain point in retinal disease care: intravitreal injections, the current standard of care, require repeat office visits that many patients struggle to keep up with.

2

The platform is licensed from the Retina Foundation of the Southwest and developed in Dr. Karl Csaky's lab, giving it an academic pedigree distinct from a pure in-house discovery program.

3

This Series A brings total funding to more than $16.5 million, a modest base for a company still in preclinical testing with a first-in-human study not planned until 2027.

4

Vinci Pharmaceuticals shares its name with an unrelated, much larger AI-chip startup that just raised a $250 million Series B -- a naming coincidence worth noting so the two don't get confused in diligence.

The VC Read

Value Add VC analysis

A bioerodible implant that removes the need for repeat injections is a genuinely differentiated mechanism if it holds up, but 2027 for first-in-human is still years from any revenue signal. We'd diligence the IND timeline and GMP manufacturing readiness closely -- this round's whole purpose is funding exactly that step, and sustained-release ocular implants have a long history of manufacturing setbacks that delay trials past initial guidance.

Analysis

Vinci Pharmaceuticals raised new venture funding for its EPIPLANT sustained-release drug delivery platform for retinal diseases, according to Pulse 2.0. Funding history:

  • Series A (new) -- more than $8 million, reportedly led by Dynagrow Capital with additional support from MintPharma Capital.
  • Seed (prior round) -- $8.5 million.
  • Total raised to date -- more than $16.5 million.

“- Series A (new) -- more than $8 million, reportedly led by Dynagrow Capital with additional support from MintPharma Capital.”

EPIPLANT is a bioerodible episcleral implant -- developed in the laboratory of Dr. Karl Csaky and licensed from the Retina Foundation of the Southwest -- designed to deliver drugs directly to retinal tissue over a sustained period, positioned as an alternative to intravitreal injections, the current standard of care for many retinal conditions. Philip A. Gioia is co-founder, chairman and CEO. The lead product, EPIPLANT VCI-002, is built around small-molecule therapies, holds multiple patents, and has completed preliminary preclinical testing; a Phase 1/2a clinical trial is expected to begin in 2027.

The pitch is aimed squarely at treatment burden: intravitreal injections require patients to return to a clinic repeatedly, often for years, and adherence drops off the longer that burden continues. Dr. Richard Lindstrom of Minnesota Eye Consultants said EPIPLANT "delivers targeted drug levels to the macula," the kind of targeted, sustained delivery the field has been chasing through implants, gels and other depot technologies for years without a clear winner yet reaching broad commercial use.

The new capital is earmarked for GMP manufacturing, testing and release activities, and preparation for that first-in-human study -- meaning this round funds the unglamorous manufacturing and regulatory groundwork a sustained-release implant needs before it can even start generating clinical data, not a near-term efficacy readout. At $16.5 million in total funding and a 2027 trial start, Vinci Pharmaceuticals is still several years and several financing rounds away from knowing whether EPIPLANT's mechanism translates into a product ophthalmologists will actually prescribe over established injection regimens.

ShareXLinkedInEmail

Key Sources

2 sources
SourcePulse 2.0
AnalysisValue Add Pulse

Reported by Pulse 2.0 · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with The VC Read, a few times a week. Free to subscribe, no spam.

Form not loading? Subscribe on Substack

Read Next

FUNDING

Fortastra Raises $30M For Maneuverable Defense Satellites

Illustration for: Fortastra Raises $30M For Maneuverable Defense Satellites
FUNDING$30M Series A

Fortastra Raises $30M For Maneuverable Defense Satellites

Fortastra raised a $30 million Series A led by First In to expand production of maneuverable spacecraft designed for on-orbit security and national defense.

FUNDING

VEIR Raises $110M For Superconducting AI Power Lines

Illustration for: VEIR Raises $110M For Superconducting AI Power Lines
FUNDING$110M Series C

VEIR Raises $110M For Superconducting AI Power Lines

VEIR closed an oversubscribed $110 million Series C, co-led by Matter Venture Partners and Tyche Partners, to scale superconducting power-delivery systems built for the energy demands of AI data centers.

FUNDING

Petra Power Pitches Fuel Cells For Data Centers

Illustration for: Petra Power Pitches Fuel Cells For Data Centers
FUNDING

Petra Power Pitches Fuel Cells For Data Centers

Petra Power, a 15-person startup building solid oxide fuel cells, is targeting both data-center operators and the Defense Department, which has already awarded it nearly $9 million in contracts.

From the Blog

Ledgebrook Raises $200M to Scale AI Insurance UnderwritingCapitolis Valuation 2026: $1.9B After a $220M RaiseFactory Valuation 2026: $5B Mark, Menlo's InvestmentLambda IPO 2027: $14.5B Valuation, $4B Round Before It

Deep Dives

Pre-Seed vs Seed vs Series A in 2026: Round Size, Valuati...Seed Hits $4.1M, Series A $19.4M — 2026 Round Benchmarks616 Days Seed to A — Series A Timeline (2026)